Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice

Keyphrases

• Intraocular Pressure 100%
• Aqueous Humor Dynamics 100%
• C-type Natriuretic Peptide 100%
• Peptide Analogs 100%
• Primary Open-angle Glaucoma 50%
• Ocular Hypertension 37%
• NPR-B 37%
• Amino Acids 25%
• IC50 25%
• EC50 25%
• Aqueous Outflow Facility 25%
• Cornea 25%
• Formation Rate 25%
• Natriuretic Peptide Receptor 25%
• Trabecular Meshwork Cells 12%
• Aqueous Humor Outflow 12%
• Outflow Facility 12%
• Mechanism of Action 12%
• Treatment Mechanisms 12%
• Novel Mechanism 12%
• Uveoscleral Outflow 12%
• Irreversible Blindness 12%
• Aqueous Humor Formation 12%
• Receptor Binding 12%
• HEK293 Cells 12%
• Pharmacologic 12%
• Modifiable Risk Factors 12%
• Cyclic Peptide 12%
• Cyclic GMP 12%
• Ligand Binding 12%
• Angiotensin II Type 1 Receptor (AT1R) 12%
• Topical Ophthalmic Administration 12%
• Binding Profile 12%
• Intraocular Injection 12%
• Ocular Hypotension 12%
• Episcleral Venous Pressure 12%
• Glaucoma Progression 12%
• Duration of Action 12%
• Disease Management 12%
• B-type Natriuretic Peptide 12%
• Cholecystokinin Receptor 12%
• Ocular Side Effects 12%
• Outflow Rate 12%
• Pressure Decrease 12%
• Natural Agonists 12%
• GMP Production 12%
• NPR-A 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Open Angle Glaucoma 100%
• Natriuretic Peptide Type C 100%
• Intraocular Hypertension 75%
• Receptor 75%
• Amino Acid 50%
• IC50 50%
• EC50 50%
• Glaucoma 25%
• Adverse Event 25%
• Disease 25%
• Antihypertensive Agent 25%
• Cyclic GMP 25%
• Cyclopeptide 25%
• Natriuretic Peptide Receptor B 25%
• Natriuretic Factor 25%
• Angiotensin 2 Receptor 25%
• Cholecystokinin A Receptor 25%

Medicine and Dentistry

• Intraocular Pressure 100%
• Aqueous Humor Flow 100%
• Natriuretic Peptide Type C 100%
• Open Angle Glaucoma 50%
• Aqueous Humor Outflow 37%
• Ocular Hypertension 37%
• IC50 25%
• Amino Acid 25%
• Trabecular Meshwork 12%
• Aqueous Humor Formation 12%
• Adverse Event 12%
• Receptor 12%
• In Vitro 12%
• Antihypertensive Agent 12%
• Venous Pressure 12%
• Disease Management 12%
• Natriuretic Factor 12%
• Receptor Binding 12%
• Ligand Binding 12%
• Risk Factor for Glaucoma 12%
• Cyclic GMP 12%
• Natriuretic Peptide Receptor B 12%
• Intraocular Drug Administration 12%
• Peptide Receptor 12%
• Cholecystokinin A Receptor 12%
• Angiotensin II Receptor Type 2 12%
• Cyclopeptide 12%